Form 4: REGENXBIO CEO Curran Simpson Sells 100 Shares Under 10b5-1 Trading Plan
SEC Form 4
REGENXBIO's CEO, Curran Simpson, executed a sale of 100 common stock shares at $15 per share on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 1, 2024, Curran Simpson, the CEO of REGENXBIO Inc. (RGNX), sold 100 shares of common stock at a price of $15 per share.
- The transaction was executed under a Rule 10b5-1 trading plan adopted on March 15, 2024.
- Following the transaction, Simpson directly owns 170,037 shares of REGENXBIO common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to an insider stock sale under a pre-arranged trading plan, indicating a neutral sentiment.
Industry Context
Sales by company executives are a normal part of corporate activity. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of adoption of the Rule 10b5-1 trading plan |
| 08/01/2024 | Date of the stock sale transaction |
| 08/05/2024 | Date of the signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.